Metabolic & Cardiometabolic
statins reduce major cardiac events only in established/advanced coronary disease (minimal benefit when CAC/CTA minimal or zero)
In plain terms: Do statins only help if a coronary calcium or CT scan already shows plaque?
Part of: 💊 statins
Contradicted: while imaging cohorts show statin benefit concentrates where coronary calcium is present, primary-prevention RCTs (e.g. JUPITER) and the CTT individual-data meta-analysis show statins cut cardiovascular events even in unscanned, lower-risk people, and the proportional benefit is independent of baseline risk — so gating benefit on pre-existing/imaged coronary disease is not supported.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mitchell 2018 · J Am Coll Cardiol | observational | supports | high | n=13,644; statin cut MACE with CAC (SHR 0.76) but NOT without CAC (SHR 1.00); interaction p<0.0001; NNT 100(CAC1-100) to 12(CAC>100) |
| CTT Collaboration 2012 · Lancet | meta-analysis | contradicts | high | IPD 27 RCTs: each 1mmol/L LDL cut gave ~21% event reduction even in lowest-risk (<5% 5yr) unscanned people; benefit not confined to imaged disease |
| Kambalapalli 2025 · Curr Atheroscler Rep | observational | mixed | moderate | Review: CAC>100 or >=75th pct marks clearest statin benefit; statins also stabilize/reduce non-calcified plaque, so CAC=0 does not equal no drug effect |
| Kalra 2026 · J Clin Lipidol | meta-analysis | contradicts | high | Primary-prevention meta-analysis found LDL-lowering reduced MACE with even larger relative risk reduction than secondary prevention, contradicting need for imaged plaque. |
| Ridker 2008 (JUPITER) venue: N Engl J Med · N Engl J Med | RCT | contradicts | high | Rosuvastatin in primary-prevention LDL<130 + high CRP (no coronary imaging selection) cut MACE 44% (HR 0.56), event in low-baseline-risk people |
| Mortensen 2018 · JACC Cardiovasc Imaging | observational | supports | moderate | MESA n=5,600: among statin-eligible, CAC=0 (44%) had low event rate; 10yr NNT 87 at CAC=0 vs 19 at CAC>100 for ASCVD |
| Kritharides 2015 · Future Cardiol | meta-analysis | contradicts | high | CTT individual-data meta-analysis of 174,000 shows proportional benefit of statins is independent of baseline risk, not requiring pre-existing coronary disease. |
| Kostapanos 2011 · World J Cardiol | RCT | contradicts | moderate | Review of the JUPITER RCT shows statins cut events and mortality in apparently healthy, normal-LDL people without prior imaging, contradicting the imaging-gated claim. |
| Charalambous 2026 · Cureus | observational | supports | low | Systematic review: CAC>0 carried 4-5x higher event risk; CAC=0 reliably predicts very low event rates, supporting risk-based statin allocation |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.